ライフサイエンスコーパス: blood substitute

1 lobin (Hb) has been evaluated as a potential blood substitute.

2 seases and/or when cell-free Hb is used as a blood substitute.

3 e blood was replaced with a hemoglobin-based blood substitute.

4 before and after isovolumic replacement with blood substitute.

5 ic blood replacement with a hemoglobin-based blood substitute.

6 romise for the production of stable Hb-based blood substitute.

7 f the oxidative toxicity of hemoglobin-based blood substitutes.

8 alues in the development of hemoglobin-based blood substitutes.

9 rable to that of erythrocytes for developing blood substitutes.

10 Hemoglobin-based blood substitutes are being developed as oxygen-carrying

11 Blood substitutes are solutions intended to replace tran

12 Blood substitutes are under development for transfusion

13 Perfluorocarbons (PFCs) are promising blood substitutes because of their chemical inertness an

14 uential robotic liquid transfers of a common blood substitute by their endothelium-lined channels (as

15 r the optimal combination of oxygen-carrying blood substitute, colloid, and electrolyte solution for

16 cations, including NO-inhalation therapy and blood substitute design.

17 regular human type-O blood into a potential blood substitute for the rare Bombay blood type.

18 application to the development of potential blood substitutes for the rare Bombay blood type that is

19 pproaches for the development of a synthetic blood substitute has been the engineering of novel mutan

20 ctive effects of cell-free, hemoglobin-based blood substitutes have been appreciated, the systemic ef

21 half of the 20th century efforts to develop blood substitutes have gained increasing momentum.

22 Hemoglobin-based blood substitutes (HBBSs) are infusible oxygen-carrying

23 ed emulsion, PFC-Oxygent, has been used as a blood substitute; however, its role in cerebral blood fl

24 usion for > 3 hours with a cold asanguineous blood substitute, hypothermosol (HTS) solution, has been

25 (O(2)) carriers not only serve as potential blood substitutes in hemorrhage but also alleviate tumor

26 rHBOCs) have several potential advantages as blood substitutes in transfusion medicine, especially in

27 iscuss the development and current status of blood substitutes, including hemoglobin-based oxygen car

28 including blood transfusion, erythropoietin, blood substitutes, iron therapy, and minimization of dia

29 The first generation of blood substitutes is currently in clinical trials.

30 ation from the clinical evaluation of these "blood substitutes" is not publicly available.

31 pirin crosslinked hemoglobin (DCHb) is a new blood substitute manufactured from human blood.

32 directed toward imaging the murine heart, a blood substitute may be applied to various optical diagn

33 Hemolink (HML) is a blood substitute of human Hb origin under development.

34 oxidation of both recombinant MbO2 and HbO2 blood substitute prototypes without altering O2 affinity

35 two crystal structures of one such potential blood substitute, recombinant (r) Hb(alpha 96Val-->Trp),

36 ndidate for the Hb-based oxygen carrier in a blood substitute system.

37 lopments for the rational design of advanced blood substitutes that aim to address unmet clinical nee

38 of materials have been studied as candidate blood substitutes: the perfluorocarbons, modified hemogl

39 d blood cell transfusion or hemoglobin-based blood substitute therapy, the hemoglobinopathies, malari

40 ermittently fluidically coupled via a common blood substitute through their reservoirs of medium and

41 The ability of cell-free hemoglobin blood substitutes to affect vascular tone through the re

42 of whole blood and dilutions of blood with a blood substitute were determined with a spectrophotomete

43 including optimization of the development of blood substitutes where Hb is contained within phospholi

44 Therefore, Hb-based blood substitutes, which are currently undergoing clinic

45 The goal is to evaluate blood substitutes with enhanced intravascular retention,